- Home
- ZURA vs GBLI Comparison
ZURA vs GBLI Comparison
Compare ZURA & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZURA | GBLI |
|---|---|---|
| Founded | 2022 | 2016 |
| Country | United States | United States |
| Employees | 30 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.8M | 395.4M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | ZURA | GBLI |
|---|---|---|
| Price | $5.78 | $28.58 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 608.4K | 1.9K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 4.90% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.75 |
| Revenue | N/A | ★ $450,098,000.00 |
| Revenue This Year | N/A | $14.23 |
| Revenue Next Year | N/A | $9.68 |
| P/E Ratio | ★ N/A | $16.33 |
| Revenue Growth | N/A | ★ 2.02 |
| 52 Week Low | $0.99 | $25.88 |
| 52 Week High | $7.25 | $34.00 |
Technical Indicators
Market Signals| Indicator | ZURA | GBLI |
|---|---|---|
| Relative Strength Index (RSI) | 47.35 | 56.64 |
| Support Level | $5.78 | $28.50 |
| Resistance Level | $6.54 | $28.81 |
| Average True Range (ATR) | 0.33 | 0.44 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 37.50 | 100.00 |
Price Performance
Historical ComparisonAbout ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC is a United States-based holding company with a diversified portfolio of property and casualty insurance-related entities. Along with its subsidiaries, the company operates in the following reportable segments: Agency and Insurance Services, Belmont Insurance Companies - Core (Belmont Core), and Belmont Insurance Companies - Non-Core (Belmont Non-Core). Maximum revenue is generated from the Belmont Core segment, which offers direct insurance and assumed reinsurance products in the E&S (Excess and Surplus) marketplace. The Agency and Insurance Services segment is focused on sourcing, underwriting, and servicing primary and assumed reinsurance business; and specialized insurance service businesses providing technology, AI-enabled marketplace, and claims services.